• February 9, 2006

    Bristol-Myers Set To Pay Shareholders $185M

    A judge has set the stage for Bristol-Myers Squibb Co. to hand out $185 million in a proposed settlement that would end a securities class action lawsuit brought by shareholders over an experimental heart drug the company touted as a future blockbuster, which later proved to be potentially fatal.

  • February 8, 2006

    New Accusations Implicate UBS in HealthSouth Scandal

    The shareholders at scandal-ridden HealthSouth Corp. have launched fresh allegations against Wall Street powerhouse UBS, accusing a handful of brokers of aiding and abetting the accounting fraud that brought one of the nation’s largest health care providers to its knees.

  • February 8, 2006

    Pfizer Takes Action Against Generics At FDA

    Generic versions of Pfizer Inc.’s antibiotic Zithromax made by Teva Pharmaceuticals U.S.A. and Novartis subsidiary Sandoz Inc. do not accurately describe the drugs' active ingredients and are a danger to consumers, according to petition filed by Pfizer with the U.S. Food and Drug Administration Wednesday.

  • February 7, 2006

    Chiron Off The Hook For Securities Violations

    The U.S. Securities and Exchange Commission has closed its investigation into whether Chiron Corp. violated any federal securities laws, the biotech company said Tuesday.

  • February 7, 2006

    Endo Presses On With Generic OxyContin Despite Risks

    Endo Pharmaceuticals’ risk-fraught decision to continue marketing its generic version of painkiller OxyContin even after losing a patent challenge at the Federal Circuit shows just how far the generics industry is willing to go in the brutally competitive marketplace, experts say.

  • February 7, 2006

    Insurance Policies Can Be Copyrighted, Judge Rules

    In what may be the first ruling of its kind, a federal court has found that insurance policies by American Family Life Assurance Co. (Aflac) were copyrightable and needed injunctive protection from competitors trying to crack into the market for supplemental insurance.

  • February 6, 2006

    Federal Circuit Reverses Priority In Claritin Battle

    In a protracted patent interference case, a pharmaceutical company hoping to trump its rival’s patent for making Claritin’s active ingredient has lost once again at the U.S. Court of Appeals for the Federal Circuit, after its inventors’ testimony was discredited by document backdating.

  • February 3, 2006

    Medisys, Roche Settle Patent Row Over Diabetics Device

    The U.S. arm of British diagnostics and medical products group Medisys has resolved its longstanding patent row with Swiss rival Roche Diagnostics Corp. over blood glucose monitors used by diabetics.

  • February 3, 2006

    Drug Co. Slapped With Securities Fraud Class Action

    Omnicare Inc., a leading provider of pharmaceutical care for the elderly, has been hit with a securities fraud class action suit filed by Lerach Coughlin Stoia Geller Rudman & Robbins LLP, claiming that the company artificially inflated its earnings by engaging in improper generic drug substitution.

  • February 2, 2006

    Medtronic Sues Biomet Over Spinal Fusion Patents

    Just a few months after medical device maker Medtronic was forced to license spinal fusion patents from a Los Angeles surgeon for a head-spinning $1.35 billion, the company is asserting three of those patents against rival Biomet Inc. and one of its subsidiaries.

  • February 2, 2006

    Cephalon, Barr End Clash Over Provigil

    Trying to stave off generic competition for as long as possible, Cephalon has reached another settlement over the narcolepsy drug Provigil, this time with generic drug maker Barr Pharmaceuticals Inc.

  • February 1, 2006

    E.U. Trumps FDA In Approval Of Biologics

    In a sign the United States and the European Union will soon be on different playing fields when it comes to generic biotechnology drugs, the European Commission has moved to grant Sandoz GmbH authority to sell human growth hormone Omnitrope, the first approved “biologic.”

  • February 1, 2006

    OxyContin Given New Lease On Life By Federal Circuit

    In a surprising turnaround, the U.S. Court of Appeals for the Federal Circuit has vacated its earlier ruling that Purdue Pharma’s patents for the blockbuster painkiller OxyContin were unenforceable, throwing the case back into the lower court’s lap for reconsideration.

  • January 31, 2006

    Feds Accuse Impath Big-Wig Of $260M Fraud Scheme

    In the kick-off to his criminal trial, federal prosecutors have accused the former president of Impath Inc. of engineering a massive accounting fraud scheme that cost shareholders $260 million and drove the medical diagnostic company straight into bankruptcy.

  • January 30, 2006

    Asbestos Companies Eye Chapter 11 Emergence

    Several companies that were crippled by class action lawsuits over cancer-causing asbestos are preparing to emerge from Chapter 11 bankruptcy protection, as attorneys and creditors committees pushed massive settlements toward approval Monday.

  • January 30, 2006

    In Blow To Sanofi, Judge Refuses To Bar Allegra Generics

    Still recovering from slumped sales of its allergy treatment Allegra, French drug maker Sanofi-Aventis was dealt another blow in federal court Friday when a judge denied a motion by the company to enjoin generic rivals from marketing the drug.

  • January 27, 2006

    Future Looks Grim For Charitable Hospitals

    Bankrupt Saint Vincent Catholic Medical Center of New York may have secured a $350 million loan from General Electric Healthcare Financial Services to help it stay afloat, but experts are predicting that charitable hospitals in general face an uncertain and bleak future.

  • January 27, 2006

    Damages Award Slashed in Laser Surgery Case

    In a blow to Nidek, the U.S. Court of Appeals for the Federal Circuit has vacated part of the damages awarded to the Japanese eye care company in the aftermath of its patent infringement battle with Summit Technology Inc. over a laser eye surgery device.

  • January 26, 2006

    Curbed At Home, India's Generic Makers Go Overseas

    Less than one year after India, one of the world’s leading supplier of generic drugs, passed a controversial measure intended to bring the country's patent regime into line with international standards, its top generics makers are under pressure to compete in a cutthroat worldwide market.

  • January 25, 2006

    Emory Fires Patent Suit At Biotech Co, Former Exec

    Emory University has taken on a biogenetics company and its former director of business development, alleging the company violated its patents and that the ex-executive allowed this infringement to take place.